iCE Neurosystems

Executive Summary

iCE Neurosystems is a medical device company pioneering a continuous brain monitoring platform for intensive care units. Its iCEWav system integrates proprietary subcutaneous EEG electrodes, bedside data acquisition software, and cloud-based analytics to provide real-time brain vital signs—a critical unmet need in critical care. By making continuous EEG monitoring practical and scalable, iCEWav aims to enable early detection of neurological deterioration, improve patient outcomes, and reduce healthcare costs. The company targets a market currently reliant on intermittent, labor-intensive traditional EEG, positioning itself as a disruptive solution for the ~5 million ICU admissions annually in the U.S. alone. Founded in 2016 and headquartered in Cambridge, MA, iCE Neurosystems has focused on product development and regulatory strategy. While the company is still pre-commercial, it has built a strong IP portfolio and is advancing toward clinical validation and regulatory submission. Key upcoming milestones include FDA 510(k) clearance for the iCEWav platform and the release of pivotal clinical data demonstrating accuracy and workflow benefits. Partners or distribution agreements with major hospital networks could accelerate adoption. With a compelling value proposition and a large addressable market, iCE Neurosystems represents a promising, if early-stage, investment opportunity in neurocritical care.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) Clearance for iCEWav Platform70% success
• Q1 2027Publication of Pivotal Clinical Study Results60% success
• Q4 2026Strategic Partnership or Distribution Agreement with Leading Hospital System50% success